Novo Nordisk has asked the FDA to block manufacture of compounded copies of copyright, arguing that it’s too hard to do safely. It’s the latest escalation within a brewing war involving pharmaceutical providers and compounders.The breakthroughs and innovations that we uncover bring about new ways of thinking, new connections, and new industries